The abstract is read at the publisher; the summary is JClub's.
In advanced metastatic colorectal cancer, Temab-A 2.4 mg/kg plus bevacizumab achieved a 30% objective response rate and improved progression-free survival versus trifluridine-tipiracil plus bevacizumab.
- Why it matters: The study addresses the need for safer, more effective options beyond standard of care in advanced CRC, testing whether adding bevacizumab can enhance Temab-A activity.
- What they did: In a randomized phase I design, patients received Temab-A 2.0 or 2.4 mg/kg with bevacizumab every 3 weeks or FTD-TPI with bevacizumab; primary objectives included safety, pharmacokinetics, and efficacy.
- The result: Temab-A 2.4 mg/kg plus bevacizumab showed tolerability with low discontinuation (1/30, 3%) and median progression-free survival of 6.8 months versus 4.2 months with FTD-TPI plus bevacizumab.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.